CD8+ T cell-mediated interface dermatitis during combination chemotherapy with mogamulizumab in a patient with adult T-cell leukaemia/lymphoma

Clin Exp Dermatol. 2018 Aug;43(6):736-737. doi: 10.1111/ced.13539. Epub 2018 May 10.

Authors

N Tani^{1

2}, K Sugita¹, A Ito¹, S Ooi³, O Yamamoto¹

Affiliations

¹ Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, 683-8504, Japan.
² Department of Dermatology, Kurume University School of Medicine, Kurume, Japan.
³ Division of Hematology, Matsue Red Cross Hospital, Matsue, Japan.

PMID: 29744911
DOI: 10.1111/ced.13539

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Asian People / ethnology
CD8-Positive T-Lymphocytes / drug effects
CD8-Positive T-Lymphocytes / immunology*
CD8-Positive T-Lymphocytes / pathology
Dermatitis / diagnosis
Dermatitis / drug therapy
Dermatitis / etiology*
Dermatitis / pathology
Drug Eruptions / complications
Drug Eruptions / diagnosis
Drug Therapy, Combination
Female
Humans
Leukemia-Lymphoma, Adult T-Cell / classification
Leukemia-Lymphoma, Adult T-Cell / drug therapy*
Leukemia-Lymphoma, Adult T-Cell / pathology
Lymph Nodes / pathology
T-Lymphocytes / drug effects
T-Lymphocytes / pathology
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
mogamulizumab